These are exciting times, with fresh news about research developments appearing every week.
Find out about the latest research news below and also visit our Breaking News in Research page.
A recent study has increased understanding of the underlying biology of sporadic inclusion body myositis (sIBM) and identified a potential therapeutic target.Read more
As part of the EU-funded PREFER project, we are helping to organise a focus group for people with myotonic dystrophy and their caregivers.
It was not known whether facioscapulohumeral muscular dystrophy (FSHD) affects bone health, and a recent study published in Muscle & Nerve begins to address this question.
A gene therapy has been shown to be safe and effective in treating mice with limb-girdle muscular dystrophy type 2E (LGMD2E).
Researchers from France and the UK have demonstrated the efficacy of micro-dystrophin gene therapy in a dog model of Duchenne muscular dystrophy.
Last month, the Developmental Endocrinology Research Group at the University of Glasgow held a one-day symposium on bone health in Duchenne muscular dystrophy.
We’re pleased to share the news that the EMA CHMP has given a positive opinion on eculizumab as a treatment for people with refractory generalised myasthenia gravis.
We would like to inform you of a research study for adults with progressive muscle weakness caused by muscular dystrophy or inclusion body myositis (IBM).
We are delighted to hear that over £28 million has been awarded to University College London (UCL) to boost research into neuromuscular conditions and other neurological conditions
Biotechnology company Scholar Rock recently announced that its myostatin inhibitor, SRK-015, will be developed as a potential treatment for spinal muscular atrophy (SMA).
PTC Therapeutics recently presented preliminary phase 2 results for RG7916 at the Cure SMA conference. RG7916 is an oral drug that could be a potential treatment for SMA.